UHCs 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)
Bacteriostatic water itself has no therapeutic activity but is an essential solvent for preparing injectable drugs such as peptides, hormones, antibiotics and other lyophilized powders, ensuring they are dissolved properly and safely prior to parenteral use
In fact, the study conducted by Romero et al
Weekly journal scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea
This regulatory capability contributes to its healing and rejuvenating effects [5]
Add caloric restriction to the equation, and both challenges intensify